Cas no 3432-99-3 (Folitixorin (~80%)(Mixture of Diastereomers))

Folitixorin (~80%) (Mixture of Diastereomers) is a chemically synthesized folinate derivative with potential applications in pharmaceutical and biochemical research. The product consists of a mixture of diastereomers, offering versatility in stereochemical studies and metabolic pathway investigations. Its high purity (~80%) ensures reliable performance in experimental settings, particularly in folate-dependent enzymatic assays or as a precursor in drug development. The diastereomeric composition may provide insights into stereoselective biological interactions, making it valuable for mechanistic studies. Suitable for controlled laboratory use, Folitixorin is handled under standard precautions to maintain stability. Researchers may find it useful for probing folate metabolism or as a reference compound in analytical applications.
Folitixorin (~80%)(Mixture of Diastereomers) structure
3432-99-3 structure
Product Name:Folitixorin (~80%)(Mixture of Diastereomers)
CAS No:3432-99-3
MF:C20H23N7O6
MW:457.439923524857
CID:306314
PubChem ID:135400185
Update Time:2025-06-08

Folitixorin (~80%)(Mixture of Diastereomers) Chemical and Physical Properties

Names and Identifiers

    • L-Glutamic acid,N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-
    • (2S)-2-[[4-(3-amino-1-oxo-4,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioic acid
    • FOLITIXORIN
    • 5,10-methylenetetrahydrofolate
    • 5,10-Methylenetetrahydrofolic acid
    • CH2H4folate
    • N5,N10-Methyl-enetetrahydrofolic Acid
    • Tetrahydromethylenefolate
    • 5,10-Methylene-5,6,7,8-tetrahydrofolate
    • N5,N10-methylene-5,6,7,8-tetrahydrofolic acid
    • 5,10-Methylenetetrahydrofolate (MTHF/Folitixorin)
    • CHEBI:20502
    • DTXSID90955873
    • n5,n10-methylenetetrahydrofolic acid
    • methylenetetrahydrofolic acid
    • 3432-99-3
    • HY-14769
    • (2S)-2-(4-(3-Amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl)benzamido)pentanedioic acid
    • 5,10-methylene-(6RS)-tetrahydrofolic acid
    • N-{4-[3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl]benzoyl}-L-glutamic acid
    • UNII-0SXY5ET48B
    • l-glutamic acid,n-(4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9h)-yl)benzoyl)-
    • 5,10-Methylene-5,6,7,8-tetrahydrofolic acid
    • N-(4-(3-Amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9H)-yl)benzoyl)-L-glutamic acid
    • SCHEMBL16413214
    • FOLITIXORIN [WHO-DD]
    • 5,10-METHYLENETETRAHYDROFOLIC ACID [DSC]
    • (2S)-2-[[4-(3-amino-1-oxo-2,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioic acid
    • N5,N10-Methylenetetrahydropteroylglutamic Acid
    • Folitixorin (~80%)
    • Folitixorin [INN]
    • N5,N10-methylene-tetrahydrofolic acid
    • SCHEMBL4097748
    • AKOS040744808
    • FOLIC ACID, TETRAHYDRO-N5,N10-METHYLENE-
    • methylenetetrahydrofolate
    • 5,10-Methylene-tetrahydrofolate
    • CS-0003550
    • Folitixorin (~80%)(Mixture of Diastereomers)
    • L-Glutamic acid, N-(4-(3-amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo(1,5-f)pteridin-8(9H)-yl)benzoyl)-
    • 5,10-methylenetetrafolate
    • QYNUQALWYRSVHF-ABLWVSNPSA-N
    • Q192838
    • MFCD19443704
    • CHEMBL117348
    • MS-28345
    • 0SXY5ET48B
    • N-[4-(3-Amino-1,2,5,6,6a,7-hexahydro-1-oxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-L-glutamic Acid
    • Folitixorin (Mixture of Diastereomers)
    • G14035
    • DB-231418
    • MDL: MFCD19443704
    • Inchi: 1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12?,13-/m0/s1
    • InChI Key: QYNUQALWYRSVHF-ABLWVSNPSA-N
    • SMILES: O=C1C2=C(N=C(N)N1)NCC1CN(C3C=CC(C(N[C@H](C(=O)O)CCC(=O)O)=O)=CC=3)CN12

Computed Properties

  • Exact Mass: 457.17100
  • Monoisotopic Mass: 457.17098148g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 7
  • Hydrogen Bond Acceptor Count: 13
  • Heavy Atom Count: 33
  • Rotatable Bond Count: 8
  • Complexity: 911
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 1
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: -0.5
  • Topological Polar Surface Area: 190?2

Experimental Properties

  • PSA: 194.97000
  • LogP: 0.47940

Folitixorin (~80%)(Mixture of Diastereomers) Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
F680350-5mg
Folitixorin (~80%)(Mixture of Diastereomers)
3432-99-3
5mg
$ 293.00 2023-09-07
TRC
F680350-50mg
Folitixorin (~80%)(Mixture of Diastereomers)
3432-99-3
50mg
$ 2274.00 2023-09-07
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
M931466-1mg
5,10-METHYLENETETRAHYDROFOLATE
3432-99-3 90%
1mg
¥4,200.00 2022-09-01
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
M931467-1mg
5,10-METHYLENETETRAHYDROFOLATE
3432-99-3 75%
1mg
¥2,097.00 2022-09-01
ChemScence
CS-0003550-1mg
Folitixorin
3432-99-3
1mg
$280.0 2022-04-27
ChemScence
CS-0003550-5mg
Folitixorin
3432-99-3
5mg
$850.0 2022-04-27
SHENG KE LU SI SHENG WU JI SHU
sc-470660-5 mg
Folitixorin (Mixture of Diastereomers),
3432-99-3
5mg
¥3,234.00 2023-07-10
SHENG KE LU SI SHENG WU JI SHU
sc-470660A-50 mg
Folitixorin (Mixture of Diastereomers),
3432-99-3
50mg
¥21,059.00 2023-07-10
SHENG KE LU SI SHENG WU JI SHU
sc-470660-5mg
Folitixorin (Mixture of Diastereomers),
3432-99-3
5mg
¥3234.00 2023-09-05
SHENG KE LU SI SHENG WU JI SHU
sc-470660A-50mg
Folitixorin (Mixture of Diastereomers),
3432-99-3
50mg
¥21059.00 2023-09-05

Folitixorin (~80%)(Mixture of Diastereomers) Related Literature

Additional information on Folitixorin (~80%)(Mixture of Diastereomers)

Research Update on Folitixorin (~80%)(Mixture of Diastereomers) and Its Relevance to CAS 3432-99-3

Folitixorin (~80%)(Mixture of Diastereomers) is a compound of significant interest in the field of chemical biology and pharmaceutical research. This research brief aims to provide an updated overview of the latest findings related to Folitixorin and its connection to the chemical identifier CAS 3432-99-3. The compound has garnered attention due to its potential therapeutic applications, particularly in the context of folate metabolism and its role in various biochemical pathways.

Recent studies have focused on the synthesis, characterization, and biological evaluation of Folitixorin. The mixture of diastereomers, with a purity of approximately 80%, has been investigated for its stability, bioavailability, and efficacy in preclinical models. Researchers have employed advanced analytical techniques, such as high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy, to elucidate the structural properties and stereochemical configuration of the compound.

One of the key findings from recent research is the potential of Folitixorin to serve as a modulator of folate-dependent enzymes. This property is particularly relevant in the context of cancer therapy, where folate metabolism is often dysregulated. Preliminary data suggest that Folitixorin may enhance the efficacy of certain chemotherapeutic agents by optimizing folate utilization in cancer cells. However, further studies are needed to validate these findings and explore the compound's mechanism of action in greater detail.

In addition to its therapeutic potential, the synthesis of Folitixorin has been a focal point of recent research. The chemical identifier CAS 3432-99-3 is often referenced in the context of precursor molecules or intermediates used in the synthesis of Folitixorin. Researchers have explored various synthetic routes to improve yield, purity, and scalability, with the goal of facilitating large-scale production for clinical applications.

The safety profile of Folitixorin has also been a subject of investigation. Toxicology studies conducted in animal models have provided preliminary evidence of the compound's safety at therapeutic doses. However, comprehensive pharmacokinetic and pharmacodynamic studies are still required to fully understand its behavior in vivo and to identify any potential side effects or drug interactions.

In conclusion, Folitixorin (~80%)(Mixture of Diastereomers) represents a promising candidate for further development in the field of chemical biology and pharmaceutical research. Its connection to CAS 3432-99-3 underscores the importance of understanding its chemical properties and synthetic pathways. While preliminary findings are encouraging, additional research is necessary to fully elucidate its therapeutic potential and safety profile. This brief highlights the need for continued exploration and collaboration among researchers to advance our understanding of this compound and its applications.

Recommended suppliers
Shandong Jing Kun Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Jing Kun Chemical Co.,Ltd.
Zouping Mingyuan Import and Export Trading Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Zouping Mingyuan Import and Export Trading Co., Ltd
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Hangzhou Cedareal Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hangzhou Cedareal Technology Co., Ltd.
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.